Shares of Sientra Inc (NASDAQ:SIEN) have received a consensus rating of “Buy” from the twelve ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $15.75.
SIEN has been the subject of a number of analyst reports. Canaccord Genuity boosted their price objective on Sientra from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. ValuEngine raised Sientra from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Maxim Group reissued a “buy” rating and set a $12.00 price objective (down from $16.00) on shares of Sientra in a research report on Friday, August 9th. Zacks Investment Research cut Sientra from a “buy” rating to a “hold” rating in a research note on Thursday, August 15th. Finally, Wells Fargo & Co upgraded Sientra from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $8.00 to $10.00 in a research note on Wednesday, June 5th.
A number of hedge funds have recently bought and sold shares of SIEN. Formula Growth Ltd. lifted its stake in Sientra by 9.1% in the first quarter. Formula Growth Ltd. now owns 120,000 shares of the medical instruments supplier’s stock valued at $1,030,000 after buying an additional 10,000 shares during the last quarter. AWM Investment Company Inc. purchased a new stake in Sientra in the second quarter valued at approximately $2,156,000. Schroder Investment Management Group purchased a new stake in Sientra in the second quarter valued at approximately $7,700,000. Stephens Inc. AR lifted its stake in Sientra by 81.1% in the second quarter. Stephens Inc. AR now owns 254,832 shares of the medical instruments supplier’s stock valued at $1,570,000 after buying an additional 114,132 shares during the last quarter. Finally, Trexquant Investment LP purchased a new stake in Sientra in the second quarter valued at approximately $172,000. Hedge funds and other institutional investors own 88.96% of the company’s stock.
Sientra (NASDAQ:SIEN) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($1.19) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.50). Sientra had a negative return on equity of 123.80% and a negative net margin of 151.96%. The company had revenue of $20.53 million for the quarter, compared to analyst estimates of $19.04 million. During the same period in the prior year, the firm posted ($0.73) earnings per share. The business’s quarterly revenue was up 17.0% compared to the same quarter last year. On average, research analysts predict that Sientra will post -2.5 earnings per share for the current fiscal year.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Recommended Story: What is a capital gains distribution?
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.